Anti-apoptotic activity

Anti-apoptotic activity refers to the biological process of inhibiting programmed cell death (apoptosis) to maintain cellular viability and tissue homeostasis [1: NIH/StatPearls]. This activity is primarily regulated by the pro-survival members of the B-cell lymphoma 2 (BCL-2) family of proteins, including BCL-2, BCL-XL, and MCL-1, which prevent mitochondrial outer membrane permeabilization (MOMP) by sequestering pro-apoptotic proteins [2: UniProt P10415]. In oncology, the pathological upregulation of anti-apoptotic activity is a hallmark of cancer, enabling malignant cells to evade death signals and develop resistance to traditional chemotherapy [3: PubMed 31548171]. Drugs known as BH3 mimetics, such as venetoclax, have been developed to specifically inhibit these pro-survival proteins, thereby restoring the cell's ability to undergo apoptosis [4: FDA Venclexta Prescribing Information]. However, therapeutic targeting of this activity presents challenges, including the risk of tumor lysis syndrome and dose-limiting toxicities in healthy tissues, such as thrombocytopenia associated with BCL-XL inhibition [5: PubMed 27151061].

Other names

Apoptosis inhibitionInhibition of apoptosisPro-survival activityProgrammed cell death inhibition

Inhibition of pro-survival BCL-2 family proteins (such as BCL-2, BCL-XL, or MCL-1) to restore the apoptotic pathway and induce programmed cell death in target cells [3, 4].